" class="no-js "lang="en-US"> Orexo Submits Application for Rescue Drug for Opioid Overdose
Tuesday, October 08, 2024

Orexo Submits New Drug Application to FDA for OX124, a High-dose Rescue Medication for Opioid Overdose

Orexo AB announces the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its lead pharmaceutical pipeline asset, OX124, a nasal rescue medication for opioid overdose. OX124, is based on Orexo´s drug delivery platform amorphOX® and contains a high-dose of naloxone.

The submission is supported by data from the pivotal study in healthy volunteers, OX124-002, where OX124 showed a significantly faster and higher absorption of naloxone compared to intramuscular dosing with an injection reference product. In addition, development formulations of OX124 have in a previous exploratory clinical study (OX124-001) in healthy volunteers, demonstrated a more rapid absorption and higher bioavailability compared with the market leading naloxone rescue medication, even with the same dose as the comparator. OX124 is protected by patents until 2039.

Opioid overdose is a life-threatening condition, characterized by loss of consciousness and respiratory depression. Opioid overdoses can be treated with the opioid antagonist naloxone. During the 12-month period ending August 2022, the predicted annual number of fatal opioid overdoses in the US exceeded 81,0001. Nine out of ten opioid overdose deaths involved synthetic opioids, including fentanyl. The switch to highly potent synthetic opioids has led to more severe overdoses, prompting the need for high-dose naloxone products.

Nikolaj Sørensen, President and CEO of Orexo AB, said: “With the filing of OX124 we are now one step closer to bringing this important product to market, providing this life-saving medication to the stigmatized and underserved patient group with opioid use disorder. From a business perspective this medication is a great strategic fit, further expanding our portfolio for patients with opioid use disorder, complementing ZUBSOLV® and MODIA®.”

The market today is solely based on prescription products but is likely to convert into a low-dose over the counter (OTC) market and a high-dose prescription market, including OX124. The increased availability of naloxone products is expected to grow the market from today’s USD 300-500 million. OX124 will, as a high-dose prescription product, have access to reimburse-ment and act in a differentiated market to the OTC market, which is likely to include the current market leader and generics thereof. The large need for potent and longer-lasting overdose rescue medications will most likely propel the prescription market. In addition, the on-going expansion of mandatory co-prescription of naloxone rescue medication will much likely also benefit the market for prescription products.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more